Adrixetinib (TFA)
Adrixetinib (Q702) TFA is a selective Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity[1][2][3].
Product Specifications
Product Name Alternative
Q702 (TFA)
UNSPSC
12352005
Target
C-Fms; TAM Receptor
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/adrixetinib-tfa.html
Concentration
10mM
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=NN(CCC)C=C1OCC(F)(F)F)NC2=NC=C(C=C2)OC3=C4C=C(OC)C(OC)=CC4=NC=C3.OC(C(F)(F)F)=O
Molecular Formula
C27H25F6N5O7
Molecular Weight
645.51
References & Citations
[1]WHO Drug Informat ion - World Health Organization (WHO) .|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Nam Kiyean, et al. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R and their preparation: World Intellectual Property Organization, WO2019229251. 2019-12-05.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items